FIELD: oncology and biotechnology.
SUBSTANCE: invention concerns conjugates used for treatment of malignant tumor. Conjugate includes staphylococcal or streptococcal wild-type superantigen or modified superantigen and antibody constituent. Bacterial superantigen is modified to reduce serum reactivity with preserved its antigenic activity. Amino acid sequence of superantigen incorporates A-E regions determining binding to TCR and MHC molecules class II. Invention is directed to preparing antitumor drug and also to preparing pharmaceutical composition.
EFFECT: use of the conjugate according to invention activate immune system and, therefore, resistance of mammalian against malignant tumor.
67 cl, 11 dwg, 1 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CONJUGATE ELICITING ABILITY TO ACTIVATE IMMUNE SYSTEM AND PHARMACEUTICAL COMPOSITION COMPRISING INDICATED CONJUGATE | 1997 |
|
RU2198895C2 |
| CONJUGATE TO STIMULATE IMMUNE RESPONSE AGAINST A TARGET CELL, METHOD TO TREAT MALIGNANT TUMORS IN MAMMALIANS | 1995 |
|
RU2183215C2 |
| SOLUBLE ANTIBODY CONJUGATE, METHOD OF TREATING ONCOLOGIC DISEASE, AND PHARMACEUTICAL COMPOSITION | 1991 |
|
RU2125889C1 |
| ANTIBODY RAISED AGAINST TO HUMAN GASTROENTERIC TRACT EPITHELIAL TUMOR ANTIGEN RELATED WITH ALPHA-6,BETA-4-INTEGRIN | 2000 |
|
RU2266298C2 |
| ANTI-KIT ANTIBODIES AND USES THEREOF | 2013 |
|
RU2681730C2 |
| STRUCTURES AIMED AT AFP/MHC PEPTIDE COMPLEXES AND TYPES OF THEIR USE | 2016 |
|
RU2754041C2 |
| USING ANTIBODIES FOR TREATING AUTOIMMUNE DISEASES IN PATIENT WITH INADEQUATE RESPONSE TO TNF-ALPHA INHIBITOR | 2008 |
|
RU2489166C2 |
| ANTIBODY-DRUG CONJUGATES (ADC) WHICH BIND TO FLT3 PROTEINS | 2016 |
|
RU2739617C2 |
| NEW ANTIBODY SHOWING SPECIFICITY TO MALIGNANT LARGE INTESTINE TUMOR | 2001 |
|
RU2268068C2 |
| COMPOSITION OF HER2 ANTIBODIES | 2005 |
|
RU2361880C2 |
